Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2014

View Archived Issues

Novel single nucleotide polymorphisms associated with bipolar disorder

NeurOp receives further NIH funding to develop cerebral ischemia candidate

Clinical data demonstrate the feasibility of roniciclib in SCLC and ovarian cancer

CellCollector may improve circulating tumor cell collection for breast cancer monitoring

Novel potent dual kinase EGFR inhibitor synthesized at Innova Pharmaceuticals

Lexicon Pharmaceuticals reports topline data for LX-4211 in type 1 diabetes

Cellceutix antibiotic shows activity against drug-resistant K. pneumoniae

Agios Pharmaceuticals begins phase I study of AG-348 in healthy volunteers

Alimera Sciences confirms new FDA action date for Iluvien

Novel sequencing method developed for the GBA gene

Scripps Research Institute launches new drug discovery initiative

Bristol-Myers Squibb patents new prodrugs of Notch signaling inhibitors

Midwestern University discloses novel FTO modulators

Covagen discloses novel IL-17A bispecific fusion proteins

NeoStem to acquire California Stem Cell and initiate phase III melanoma trial

VPM-1002 shows favorable preclinical and early clinical profile for the treatment of bladder cancer

Aapa BV discloses new SERT inhibitors and 5-HT2C receptor antagonists

Peginterferon alfa-2b follow-on biologic is noninferior in phase II/III trial

Ziarco Pharma presents novel SYK kinase inhibitors

FDA approves clinical trial initiation for Vivolux's mitochondria-targeting agent

DesignMedix receives NIH grant for antimalarial drug

FDA accepts NDA filing for Boehringer Ingelheim/Lilly diabetes combination tablet

Bristol-Myers Squibb files NDA for HIV-1 fixed-dose combination tablet

Grastek immunotherapy for grass pollen-induced allergic rhinitis approved by FDA

Phase III Livatag study recommended to continue by safety board

Critical Pharmaceuticals and University of Nottingham initiate first-in-human trial in osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...